Nature's Bounty names long-time OTC consumer vet to the helm

Press enter to search
Close search
Open Menu

Nature's Bounty names long-time OTC consumer vet to the helm

By Michael Johnsen - 09/28/2017

NEW YORK — Nature's Bounty on Thursday announced the closing of the transaction with global investment firm, KKR, which is now the majority owner of Nature’s Bounty.



Effective upon the transaction close, consumer healthcare veteran Paul Sturman will assume the role of CEO Nature’s Bounty. Sturman succeeds Steve Cahillane, who is stepping down to pursue another opportunity.



“Paul is a very well regarded leader in the consumer healthcare space, having grown and transformed several companies and brands over the years,” stated Nate Taylor, head of consumer retail at KKR.  “He’s a great fit to lead Nature’s Bounty in its next stage of growth.”



“There are tremendous opportunities to grow Nature’s Bounty’s footprint in this rapidly expanding global wellness industry, and I look forward to working with the many talented people at Nature’s Bounty to provide the company’s valued customers with the world’s best health and wellness offerings,” Sturman said.   



Sturman has a strong track record of more than 30 years of experience in the consumer healthcare sector with Pfizer, Johnson & Johnson and Warner-Lambert. Sturman  spent six years successfully leading Pfizer’s more than $3 billion consumer healthcare business (formerly Wyeth) with major household brands such as Advil, Centrum, Chapstick, Nexium 24Hour, Robitussin and Emergen-C.  He also served as president of Johnson & Johnson’s North American Consumer Health Care business, where he was responsible for more than 30 brands including Listerine, Band-Aid, Stayfree, Monistat, Rogaine, Neosporin and Visine.



Sturman also previously served as chairman of the Consumer Health Products Association.  He is currently a Trustee of the Foundation for Morristown Medical Center and is on the board of directors of Tyme, a clinical-stage biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics with low toxicity profiles.